Would-be deal partners Johnson & Johnson and Actelion are onto their second round of talks, and this time, Actelion may just get the transaction it’s been hoping for.
The pair is hammering out a pact that would split Actelion’s commercialized meds from its R&D assets, sources tell Reuters. Actelion’s pipeline prospects would spin off into a new publicly traded company, while J&J would snap up the marketed meds with a cash offer in the neighborhood of $260 per share—slightly more than the figure the New Jersey company offered up before throwing in the towel last month.
Who would own the newly spun-off company—and whether Actelion founder and CEO Jean-Paul Clozel would run it—are still up for discussion, the sources said, but the companies could have an arrangement worked out by late this month.
Actelion, whose execs have been outspoken about their desire to stay solo, reportedly pushed J&J for a deal more complex than an outright buy when the pharma giant first came calling. But after two months-plus of back-and-forth with tough customer Clozel, J&J walked.
The move was fine by Actelion, which had another suitor in M&A-hungry Sanofi. But with the French behemoth reportedly ready to hand over $30 billion, J&J decided to get back into the mix, and Actelion returned to exclusive talks with its first-choice buyer.
The reason for that may hinge on J&J’s willingness to consider alternative deal types. Clozel, who founded the company with his wife Martine—Actelion’s chief scientific officer—after leaving an exec post at Roche, has touted Actelion’s standalone potential for years, dodging an $18.9 billion bid from fellow rare-disease drugmaker Shire and recording a 2011 triumph over activist hedge fund Elliott Advisors.
If Clozel did take the helm of the new entity, he would be able to continue presiding over a pipeline that includes candidates for pulmonary arterial hypertension—the therapeutic area that’s anchored Actelion’s success—as well as Clostridium difficile and multiple sclerosis.
J&J, meanwhile, would inherit moneymakers including Opsumit and Uptravi, meds that have stepped in to fill the void left by aging PAH star Tracleer. J&J’s own lead med, Remicade, is newly up against biosimilar competition from Pfizer in the U.S., making it an ideal time to bring in a new revenue stream.
By Carly Helfand
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
